An Update on the Management of Budd–Chiari Syndrome

• Published in: Digestive diseases and sciences 2021-06, Vol.66 (6), p.1780-1790
• Main Authors: Sharma, A., Keshava, S. N., Eapen, A., Elias, E., Eapen, C. E.
• Format: Article
• Language: English
• Subjects: Angioplasty - trends; Biochemistry; Budd-Chiari Syndrome - diagnostic imaging; Budd-Chiari Syndrome - physiopathology; Budd-Chiari Syndrome - therapy; Care and treatment; Development and progression; Disease; Disease Management; Endovascular Procedures - trends; Etiology; Gastroenterology; Hepatology; Humans; Hypertension; Liver; Liver Transplantation - trends; Medicine; Medicine & Public Health; Mutation; Oncology; Pathology; Patients; Review; Thrombolytic Therapy - trends; Thrombosis; Transplant Surgery; Veins & arteries
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/s10620-020-06485-y

Budd–Chiari syndrome (BCS) is an uncommon condition, caused by obstruction to hepatic venous outflow. It is largely underdiagnosed, and a high index of suspicion is required for any patient with unexplained portal hypertension. The understanding of its etiology and pathology is improving with advances in diagnostic techniques. Recent studies reported an identifiable etiology in > 80% of cases. Myeloproliferative neoplasm (MPN) is the most common etiology, and genetic studies help in diagnosing latent MPN. Better cross-sectional imaging helps delineate the site of obstruction accurately. The majority of BCS patients are now treated by endovascular intervention and anticoagulation which have improved survival in this disease. Angioplasty of hepatic veins/inferior vena cava remains under-utilized at present. While surgical porto-systemic shunts are no longer done for BCS, liver transplantation is reserved for select indications. Some of the unresolved issues in the current management of BCS are also discussed in this review.